COMT Val158Met, but not BDNF Val66Met, is associated with white matter abnormalities of the temporal lobe in patients with first-episode, treatment-naïve major depressive disorder: A diffusion tensor imaging study

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1183-1190

  Hayashi, Kenji ^a   Yoshimura, Reiji ^a   Kakeda, Shingo ^b   Kishi, Taro ^c   Abe, Osamu ^d   Umene Nakano, Wakako ^a   Katsuki, Asuka ^a   Hori, Hikaru ^a   Ikenouchi Sugita, Atsuko ^a   Watanabe, Keita ^b   Ide, Satoru ^b   Ueda, Issei ^b   Moriya, Junji ^b   Iwata, Nakao ^c   Korogi, Yukunori ^b   Kubicki, Marek ^e   Nakamura, Jun ^a  

^a Department of Psychiatry ^*  (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

^d NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

3 methoxy 4 hydroxyphenylglycol; Brain derived neurotrophic factor; Catechol o methyltransferase; Homovanillic acid

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; HOMOVANILLIC ACID;

ADULT; AGED; ARTICLE; AXIAL DIFFUSIVITY; BDNF GENE; CLINICAL ARTICLE; COMT GENE; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; FEMALE; FRACTIONAL ANISOTROPY; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMAGE PROCESSING; MAJOR DEPRESSION; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SCANNER; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; RADIAL DIFFUSIVITY; RADIOLOGICAL PARAMETERS; TEMPORAL LOBE; WHITE MATTER LESION;

EID: 84903374137     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S61275     Document Type: Article

References (51)

1. Yoshimura R, Nakamura J, Shinkai K, Ueda N. Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(4): 611-616.
2. Karege F, Bovier P, Gaillard JM, Tissot R. The decrease of erythrocyte catechol-O-methyltransferase activity in depressed patients and its diagnostic significance. Acta Psychiatr Scand. 1987;76(3): 303-308.
3. Massat I, Souery D, Del-Favero J, et al. Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Mol Psychiatry. 2005;10(6):598-605.
4. Lachman HM, Morrow B, Shprintzen R, et al. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet. 1996;67(5):468-472.
5. Baune BT, Hohoff C, Berger K, et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacolog y. 2008;33(4):924-932.
6. Åberg E, Fandiño-Losada A, Sjöholm LK, Forsell Y, Lavebratt C. The functional Val158Met polymorphism in catechol-O-methyltransferase (COMT) is associated with depression and motivation in men from a Swedish population-based study. J Affect Disord. 2011;129(1-3):158-166.
7. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci. 2007;10(9):1089-1093.
8. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatry. 2000;157(1):115-118.
9. Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol. 2010;70(5):289-297.
10. Thompson Ray M, Weickert CS, Wyatt E, Webster MJ. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci. 2011;36(3):195-203.
11. Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry. Epub August 20, 2013.
12. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112(2):257-269.
13. Frielingsdorf H, Bath KG, Soliman F, Difede J, Casey BJ, Lee FS. Variant brain-derived neurotrophic factor Val66Met endophenotypes: implications for posttraumatic stress disorder. Ann N Y Acad Sci. 2010;1208:150-157.
14. Aanhetrot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ. 2009;180(3):305-313.
15. Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci. 2008;31(7):361-370.
16. Herrmann LL, Le Masurier M, Ebmeier KP. White matter hyperintensities in late life depression: a systematic review. J Neurol Neurosurg Psychiatry. 2008;79(6):619-624.
17. Kumar A, Cook IA. White matter injury, neural connectivity and the pathophysiology of psychiatric disorders. Dev Neurosci. 2002;24(4): 255-261.
18. Kieseppä T, Eerola M, Mäntylä R, et al. Major depressive disorder and white matter abnormalities: a diffusion tensor imaging study with tract-based spatial statistics. J Affect Disord. 2010;120(1-3):240-244.
19. Korgaonkar MS, Grieve SM, Koslow SH, Gabrieli JD, Gordon E, Williams LM. Loss of white matter integrity in major depressive disorder: evidence using tract-based spatial statistical analysis of diffusion tensor imaging. Hum Brain Mapp. 2011;32(12):2161-2171.
20. Zhu X, Wang X, Xiao J, Zhong M, Liao J, Yao S. Altered white matter integrity in frst-episode, treatment-naive young adults with major depressive disorder: a tract-based spatial statistics study. Brain Res. 2011;1369:223-229.
21. Cullen KR, Klimes-Dougan B, Mueller BA, et al. Altered white matter microstructure in adolescents with major depression: A preliminary study. J Am Acad Child Adolesc Psychiatry. 2010;49(2):173-183.
22. Zuo N, Fang J, Lv X, et al. White matter abnormalities in major depression: a tract-based spatial statistics and rumination study. PLoS One. 2012;7(5):e37561.
23. Sexton CE, Mackay CE, Ebmeier K P. A systematic review of diffusion tensor imaging studies in affective disorders. Biol Psychiatry. 2009;66(9):814-823.
24. Henderson CE, Higginson JS, Barrance PJ. Comparison of MRI-based estimates of articular cartilage contact area in the tibiofemoral joint. J Biomech Eng. 2011;133(1)014502.
25. Ma N, Li L, Shu N, et al. White matter abnormalities in first-episode, treatment-naive young adults with major depressive disorder. Am J Psychiatry. 2007;164(5):823-826.
26. Wu F, Tang Y, Xu K, et al. Whiter matter abnormalities in medication-naive subjects with a single short-duration episode of major depressive disorder. Psychiatry Res. 2011;191(1):80-83.
27. Ouyang X, Tao HJ, Liu HH, et al. White matter integrity defcit in treatment-naïve adult patients with major depressive disorder. East Asian Arch Psychiatry. 2011;21(1):5-9.
28. Jia Z, Huang X, Wu Q, et al. High-feld magnetic resonance imaging of suicidality in patients with major depressive disorder. Am J Psychiatry. 2010;167(11):1381-1390.
29. de Diego-Adeliño J, Pires P, Gómez-Ansón B, et al. Microstructural white-matter abnormalities associated with treatment resistance, severity and duration of illness in major depression. Psychol Med. Epub August 21, 2013.
30. Liao Y, Huang X, Wu Q, et al. Is depression a disconnection syndrome? Meta-analysis of diffusion tensor imaging studies in patients with MDD. J Psychiatry Neurosci. 2012;38(1):49-56.
31. Carballedo A, Amico F, Ugwu I, et al. Reduced fractional anisotropy in the uncinate fasciculus in patients with major depression carrying the met-allele of the Val66Met brain-derived neurotrophic factor genotype. Am J Med Genet B Neuropsychiatr Genet. 2012;159B(5):537-548.
32. Kim B, Yo o E, Lee JY, et al. The effects of the catechol-O-methyltransferase val158met polymorphism on white matter connectivity in patients with panic disorder. J Affect Disord. 2013;147(1-3):64-71.
33. Haselgrove JC, Moore JR. Correction for distortion of echo-planar images used to calculate the apparent diffusion coeffcient. Magn Reson Med. 1996;36(6):960-964.
34. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23 Suppl 1:S208-S219.
35. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage. 2006;31(4):1487-1505.
36. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17(3):143-155.
37. Rueckert D, Sonoda LI, Hayes C, Hill DL, Leach MO, Hawkes DJ. Nonrigid registration using free-form deformations: application to breast MR images. IEEE Trans Med Imaging. 1999;18(8):712-721.
38. Yeung PK, Buckley SJ, Pedder SC, Dingemanse J. Determination of 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid in human plasma by a simple and rapid high-performance liquid chromatography assay. J Pharm Sci. 1996;85(4):451-453.
39. Minegishi A, Ishizaki T. Determination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr. 1984;311(1):51-57.
40. Brett M, Leff A P, Rorden C, Ashburner J. Spatial normalization of brain images with focal lesions using cost function masking. Neuroimage. 2001;14(2):486-500.
41. Seok JH, Choi S, Lim HK, Lee SH, Kim I, Ham BJ. Effect of the COMT val158met polymorphism on white matter connectivity in patients with major depressive disorder. Neurosci Lett. 2013;545:35-39.
42. Ueda N, Yoshimura R, Shinkai K, Nakamura J. Plasma levels of catecholamine metabolites predict the response to sulpiride or fuvoxamine in major depression. Pharmacopsychiatry. 2002;35(5): 175-181.
43. Shinkai K, Yoshimura R, Ueda N, Okamoto K, Nakamura J. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol. 2004;24(1):11-17.
44. Stuhrmann A, Dohm K, Kugel H, et al. Mood-congruent amygdala responses to subliminally presented facial expressions in major depression: associations with anhedonia. J Psychiatry Neurosci. 2013;38(4):249-258.
45. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related defcits. Trends Neurosci. 2012;35(1):68-77.
46. Green S, Lambon Ralph MA, Moll J, Deakin JF, Zahn R. Guilt-selective functional disconnection of anterior temporal and subgenual cortices in major depressive disorder. Arch Gen Psychiatry. 2012;69(10): 1014-1021.
47. Sneed JR, Rindskopf D, Steffens DC, Krishnan KR, Roose SP. The vascular depression subtype: evidence of internal validity. Biol Psychiatry. 2008;64(6):491-497.
48. Li L, Ma N, Li Z, et al. Prefrontal white matter abnormalities in young adult with major depressive disorder: a diffusion tensor imaging study. Brain Res. 2007;1168:124-128.
49. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry. 2010;11(6):763-773.
50. Fernandes BS, Gama CS, Ceresér KM, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45(8):995-1004.
51. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008;64(6):527-532.